Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  Habre, Walid ^a   Albu, Gergely ^a   Janosi, Tibor Z ^a   Fontao, Fabienne ^a   von Ungern Sternberg, Britta S ^a   Beghetti, Maurice ^b   Petak, Ferenc ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Geneva Children's Hospital   (Switzerland)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; METHACHOLINE; SILDENAFIL; TEZOSENTAN; ANTIHYPERTENSIVE AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PROSTACYCLIN DERIVATIVE; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONE; TETRAZOLE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASODILATOR AGENT;

ADULT; AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTICLE; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FORCED OSCILLATION TECHNIQUE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; NONHUMAN; OSCILLATION; OSMOTIC PUMP; PATHOGENESIS; PULMONARY HYPERTENSION; RAT; ANALYSIS OF VARIANCE; ANIMAL; BLOOD PRESSURE; BRONCHOSPASM; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; INFUSION; INFUSION PUMP; INHALATION TEST; LUNG; LUNG VOLUME; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TIME; VASCULARIZATION;

ADMINISTRATION, ORAL; AIRWAY RESISTANCE; ANALYSIS OF VARIANCE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; DISEASE MODELS, ANIMAL; ENDOTHELINS; HYPERTENSION, PULMONARY; ILOPROST; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, PARENTERAL; LUNG; LUNG VOLUME MEASUREMENTS; MALE; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSTAGLANDINS I; PURINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION; SULFONES; TETRAZOLES; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE; VASODILATOR AGENTS;

EID: 79955166046     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-58     Document Type: Article

References (40)

1. Hoeper MM, Rubin LJ: Update in pulmonary hypertension 2005. Am J Respir Crit Care Med 2006, 173:499-505.
2. McLaughlin VV, Genthner DE, Panella MM, Rich S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998, 338:273-277.
3. Murali S: Pulmonary arterial hypertension. Curr Opin Crit Care 2006, 12:228-234.
4. Rich S: The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 2006, 130:1198-1202.
5. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
6. Howard LS, Morrell NW: New therapeutic agents for pulmonary vascular disease. Paediatr Respir Rev 2005, 6:285-291.
7. Keith IM: The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol Res 2000, 49:519-537.
8. Habre W, Petak F, Ruchonnet-Metrailler I, Donati Y, Tolsa JF, Lele E, Albu G, Beghetti M, Barazzone-Argiroffo C: The role of endothelin-1 in hyperoxia-induced lung injury in mice. Respir Res 2006, 7:45.
9. Ghofrani HA, Osterloh IH, Grimminger F: Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006, 5:689-702.
10. Janosi T, Petak F, Fontao F, Morel DR, Beghetti M, Habre W: Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung. Exp Physiol 2008, 93:1210-1219.
11. von Ungern-Sternberg BS, Habre W, Regli A, Pache JC, Fontao F, Janosi TZ, Beghetti M, Petak F: Precapillary pulmonary hypertension leads to reversible bronchial hyperreactivity in rats. Exp Lung Res 2010, 36:129-139.
12. Garcia R, Diebold S: Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res 1990, 24:430-432.
13. Ocampo C, Ingram P, Ilbawi M, Arcilla R, Gupta M: Revisiting the surgical creation of volume load by aorto-caval shunt in rats. Mol Cell Biochem 2003, 251:139-143.
14. Habre W, Janosi TZ, Fontao F, Meyers C, Albu G, Pache JC, Petak F: Mechanisms for lung function impairment and airway hyperresponsiveness following chronic hypoxia in rats. Am J Physiol Lung Cell Mol Physiol 2010, 298:L607-614.
15. Janosi TZ, Adamicza A, Zosky GR, Asztalos T, Sly PD, Hantos Z: Plethysmographic estimation of thoracic gas volume in apneic mice. J Appl Physiol 2006, 101:454-459.
16. Petak F, Hantos Z, Adamicza A, Asztalos T, Sly PD: Methacholine-induced bronchoconstriction in rats: effects of intravenous vs. aerosol delivery. J Appl Physiol 1997, 82:1479-1487.
17. Petak F, Habre W, Hantos Z, Sly PD, Morel DR: Effects of pulmonary vascular pressures and flow on airway and parenchymal mechanics in isolated rat lungs. J Appl Physiol 2002, 92:169-178.
18. Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ: Input impedance and peripheral inhomogeneity of dog lungs. J Appl Physiol 1992, 72:168-178.
19. Petak F, Hall GL, Sly PD: Repeated measurements of airway and parenchymal mechanics in rats by using low-frequency oscillations. J Appl Physiol 1998, 84:1680-1686.
20. Lam CF, Peterson TE, Croatt AJ, Nath KA, Katusic ZS: Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2005, 289:H2334-2341.
21. Larsen GL, Loader J, Fratelli C, Kang JK, Dakhama A, Colasurdo GN: Modulation of airway responses by prostaglandins in young and fully grown rabbits. Am J Physiol Lung Cell Mol Physiol 2007, 293:L239-244.
22. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004, 84:731-765.
23. Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S: Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998, 79:175-179.
24. Gomberg-Maitland M, Olschewski H: Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008, 31:891-901.
25. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
26. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
27. Brown RH, Zerhouni EA, Hirshman CA: Reversal of bronchoconstriction by inhaled nitric oxide. Histamine versus methacholine. Am J Respir Crit Care Med 1994, 150:233-237.
28. Hogman M, Frostell C, Arnberg H, Hedenstierna G: Inhalation of nitric oxide modulates methacholine-induced bronchoconstriction in the rabbit. Eur Respir J 1993, 6:177-180.
29. MacLean MR, McCulloch KM, Baird M: Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 1994, 23:838-845.
30. Leuchte HH, Meis T, El-Nounou M, Michalek J, Behr J: Inhalation of endothelin receptor blockers in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008, 294:L772-777.
31. Opitz CF, Ewert R, Kirch W, Pittrow D: Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008, 29:1936-1948.
32. Anaid S, Petkov V, Baykuscheva-Gentscheva T, Hoeger H, Painsipp E, Holzer P, Mosgoeller W: Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Regul Pept 2007, 139:102-108.
33. Iwabuchi S, Ono S, Tanita T, Koike K, Fujimura S: Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung. Respiration 1997, 64:54-58.
34. Crimi N, Palermo F, Oliveri R, Palermo B, Vancheri C, Polosa R, Mistretta A: Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction. J Allergy Clin Immunol 1988, 82:617-621.
35. Hagen BM, Bayguinov O, Sanders KM: VIP and PACAP regulate localized Ca2+ transients via cAMP-dependent mechanism. Am J Physiol Cell Physiol 2006, 291:C375-385.
36. Kishi M, Takeuchi T, Suthamnatpong N, Ishii T, Nishio H, Hata F, Takewaki T: VIP- and PACAP-mediated nonadrenergic, noncholinergic inhibition in longitudinal muscle of rat distal colon: involvement of activation of charybdotoxin- and apamin-sensitive K+ channels. Br J Pharmacol 1996, 119:623-630.
37. Lee TJ: Nitric oxide and the cerebral vascular function. J Biomed Sci 2000, 7:16-26.
38. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003, 111:1339-1346.
39. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J: Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008, 32:1289-1294.
40. Barnes PJ, Dixon CM: The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis 1984, 130:162-166.